Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SRDX | Common Stock | Options Exercise | $88.1K | +4.37K | +14.46% | $20.18 | 34.6K | Feb 28, 2022 | Direct | |
transaction | SRDX | Common Stock | Sale | -$196K | -4.37K | -12.63% | $44.97 | 30.2K | Feb 28, 2022 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SRDX | Stock Option (right to buy) | Options Exercise | $0 | -4.37K | -100% | $0.00* | 0 | Feb 28, 2022 | Common Stock | 4.37K | $20.18 | Direct | F3 |
Id | Content |
---|---|
F1 | Reflects the weighted average price of 4,366 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on February 28, 2022 with sale prices ranging from $44.96 to $45.08 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
F2 | The amount beneficially owned includes 13,203 restricted stock units (RSUs) that vest on service-based vesting dates that will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. |
F3 | Fully vested. |